Bowel cancer drugs ban a scandal, say campaigners

Two drugs hailed as a huge advance in treating bowel cancer will not be approved for use on the NHS, the Government's health watchdog said today.











Campaigners said the move by the National Institute for Health and Clinical Excellence (Nice) was a "backward step" and thousands of patients would die early as a result.



The watchdog rejected Avastin (bevacizumab) and Erbitux (cetuximab) for treating advanced bowel cancer, saying the drugs were not cost-effective.



Its last-stage draft guidance could be subject to an appeal but a final version is expected in November.



Hilary Whittaker, chief executive of Beating Bowel Cancer, branded the decision a "scandal" and said the drug was widely available across Europe.



"Why should patients in the UK be worse off than patients in the rest of Europe?," she said. "It just doesn't add up."



Michael Wickham, chief executive of Bowel Cancer UK, said the decision was "further proof that the NHS is simply not working for bowel cancer patients and is overdue a full and comprehensive review".



The Government was content with a £10bn overspend on its controversial IT programme yet patients were denied treatments "that can help them live longer and better lives", he added.



The NHS of 2006 was content for patients to have to go private and "to spend their often limited time and energy fighting bureaucracy rather than the disease", he continued.



Bowel cancer is the third most common cancer in the UK and 35,000 people are newly-diagnosed every year.



Around 16,000 people die from it every year and more than half of new cases reach the advanced stage, which Avastin and Erbitux are designed to treat.



The therapies have been shown to extend survival by an average of five months and work by specifically targeting cancer cells.



Erbitux, which costs around £700 a week, has been shown to shrink tumours allowing the possibility of surgery, but neither drug is a cure.



Dr Mark Saunders, consultant clinical oncologist at the Christie Hospital NHS Trust, said: "Not only is this a sad day for bowel cancer patients, but also for oncologists in the UK, who want to offer their patients the best possible range of treatments.



"In other European countries, oncologists can use Erbitux and get the cost reimbursed. Why should patients and oncologists in the UK be treated any differently? Today's decision signals a backward step for bowel cancer."



The decision was also branded ironic, given that British scientists led the way in Erbitux clinical trials.



Erbitux has been available to Welsh patients since it was approved by Assembly Health Minister Brian Gibbons in June.



But that decision will now be overturned and an Assembly Government spokeswoman said Mr Gibbons was "highly unlikely" to appeal.



Joanne Rule, Cancerbackup chief executive, said pharmaceutical companies also needed to do more to make their treatments meet the Nice affordability threshold.



She added: "There must surely be smarter ways to negotiate on price. We urge the manufacturers, the Department of Health and Nice to meet urgently to find ways to make cancer treatments more affordable.



"Without change, we will simply perpetuate a two-tier system in which important treatments will only be available to those who can afford to pay."



Andrea Sutcliffe, deputy chief executive of Nice, said: "Following consultation on the first draft guidance, our assessment of the evidence, which shows that neither of these drugs represents a good use of scarce NHS resources, has not changed.



"Although bevacizumab does show some increased benefit over standard treatment, the appraisal committee was not persuaded that it was cost- effective in the treatment of metastatic colorectal cancer.



"The evidence available on cetuximab does not compare it with current standard treatment and therefore we are not able to assess whether it is any better than existing treatments or whether the NHS could justify spending money on the drug."

News
More than 90 years of car history are coming to an end with the abolition of the paper car-tax disc
newsThis and other facts you never knew about the paper circle - completely obsolete today
News
people'I’d rather have Fred and Rose West quote my characters on childcare'
Life and Style
The new Windows 10 Start Menu
tech
Arts and Entertainment
There has been a boom in ticket sales for female comics, according to an industry survey
comedyFirst national survey reveals Britain’s comedic tastes
PROMOTED VIDEO
Life and Style
ebooksA superb mix of recipes serving up the freshest of local produce in a delicious range of styles
Life and Style
ebooksFrom the lifespan of a slug to the distance to the Sun: answers to 500 questions from readers
Travel
Bruce Chatwin's novel 'On the Black Hill' was set at The Vision Farm
travelOne of the finest one-day walks you could hope for - in Britain
Sport
footballManchester City 1 Roma 1: Result leaves Premier League champions in danger of not progressing
Arts and Entertainment
Gay and OK: a scene from 'Pride'
filmsUS film censors have ruled 'Pride' unfit for under-16s, though it contains no sex or violence
News
i100
Life and Style
Magic roundabouts: the gyratory system that has excited enthusiasts in Swindon
motoringJust who are the Roundabout Appreciation Society?
Arts and Entertainment
Hilary North's 'How My Life Has Changed', 2001
booksWell it was good enough for Ancient Egyptians and Picasso...
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Commercial Litigation NQ+

    Very Competitive Salary: Austen Lloyd: NORTH HAMPSHIRE NQ to MID LEVEL - An e...

    MANCHESTER - SENIOR COMMERCIAL LITIGATION -

    Highly Attractive Pakage: Austen Lloyd: MANCHESTER - A highly attractive oppor...

    Senior Marketing Manager - Central London - £50,000

    £40000 - £50000 per annum: Ashdown Group: Marketing Manager (Campaigns, Offlin...

    Head of Marketing - Acquisition & Direct Reponse Marketing

    £90000 - £135000 per annum: Ashdown Group: Head of Marketing (B2C, Acquisition...

    Day In a Page

    Ebola outbreak: The children orphaned by the virus – then rejected by surviving relatives over fear of infection

    The children orphaned by Ebola...

    ... then rejected by surviving relatives over fear of infection
    Pride: Are censors pandering to homophobia?

    Are censors pandering to homophobia?

    US film censors have ruled 'Pride' unfit for under-16s, though it contains no sex or violence
    The magic of roundabouts

    Lords of the rings

    Just who are the Roundabout Appreciation Society?
    Why do we like making lists?

    Notes to self: Why do we like making lists?

    Well it was good enough for Ancient Egyptians and Picasso...
    Hong Kong protests: A good time to open a new restaurant?

    A good time to open a new restaurant in Hong Kong?

    As pro-democracy demonstrators hold firm, chef Rowley Leigh, who's in the city to open a new restaurant, says you couldn't hope to meet a nicer bunch
    Paris Fashion Week: Karl Lagerfeld leads a feminist riot on 'Boulevard Chanel'

    Paris Fashion Week

    Lagerfeld leads a feminist riot on 'Boulevard Chanel'
    Bruce Chatwin's Wales: One of the finest one-day walks in Britain

    Simon Calder discovers Bruce Chatwin's Wales

    One of the finest one-day walks you could hope for - in Britain
    10 best children's nightwear

    10 best children's nightwear

    Make sure the kids stay cosy on cooler autumn nights in this selection of pjs, onesies and nighties
    Manchester City vs Roma: Five things we learnt from City’s draw at the Etihad

    Manchester City vs Roma

    Five things we learnt from City’s Champions League draw at the Etihad
    Martin Hardy: Mike Ashley must act now and end the Alan Pardew reign

    Trouble on the Tyne

    Ashley must act now and end Pardew's reign at Newcastle, says Martin Hardy
    Isis is an hour from Baghdad, the Iraq army has little chance against it, and air strikes won't help

    Isis an hour away from Baghdad -

    and with no sign of Iraq army being able to make a successful counter-attack
    Turner Prize 2014 is frustratingly timid

    Turner Prize 2014 is frustratingly timid

    The exhibition nods to rich and potentially brilliant ideas, but steps back
    Last chance to see: Half the world’s animals have disappeared over the last 40 years

    Last chance to see...

    The Earth’s animal wildlife population has halved in 40 years
    So here's why teenagers are always grumpy - and it's not what you think

    Truth behind teens' grumpiness

    Early school hours mess with their biological clocks
    Why can no one stop hackers putting celebrities' private photos online?

    Hacked photos: the third wave

    Why can no one stop hackers putting celebrities' private photos online?